Treats CMV retinitis. ANDA 205166, held by Hetero Labs Ltd V. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 205166 (Valganciclovir Hydrochloride), held by Hetero Labs Ltd V, was first approved by FDA on Mar 18, 2016, with 3 approved supplements and 0 published complete response letters.
Valganciclovir tablets are a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 18, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir HydrochlorideEQ 450MG BASE · tablet;oral | Valganciclovir Hydrochloride | Rx |
| Aug 18, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Aug 18, 2022 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 12, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 18, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters